François P. Bischoff*, Sven Van Brandt, Marcel Viellevoye, Michel De Cleyn, Michel Surkyn, Rodrigo J. Carbajo, Maria Dominguez Blanco, Berthold Wroblowski, Nathan K. Karpowich, Ruth A. Steele, Celine Schalk-Hihi, Robyn Miller, David Duda, Paul Shaffer, Scott Ballentine, Sirak Simavorian, Brian Lord, Robert A. Neff, Pascal Bonaventure and Harrie J. M. Gijsen*,
{"title":"GluN2A负变构调节剂的设计、合成和表征","authors":"François P. Bischoff*, Sven Van Brandt, Marcel Viellevoye, Michel De Cleyn, Michel Surkyn, Rodrigo J. Carbajo, Maria Dominguez Blanco, Berthold Wroblowski, Nathan K. Karpowich, Ruth A. Steele, Celine Schalk-Hihi, Robyn Miller, David Duda, Paul Shaffer, Scott Ballentine, Sirak Simavorian, Brian Lord, Robert A. Neff, Pascal Bonaventure and Harrie J. M. Gijsen*, ","doi":"10.1021/acs.jmedchem.4c0275110.1021/acs.jmedchem.4c02751","DOIUrl":null,"url":null,"abstract":"<p ><i>N</i>-Methyl-<span>d</span>-aspartate receptors are ionotropic glutamate receptors that mediate fast excitatory neurotransmission in the central nervous system. These receptors play essential roles in synaptic plasticity, learning, and memory and are implicated in various neuropathological and psychiatric disorders. Selective modulation of NMDAR subtypes, particularly GluN2A, has proven challenging. The <b>TCN-201</b> derivatives <b>MPX-004</b> and <b>MPX-007</b> are potent and selective for GluN2A receptors, yet their physical properties limit their in vivo utility. In this study, we optimized the <b>MPX-004</b>/<b>MPX-007</b> scaffold by modifying the linker region between the distal halogenated aromatic ring and the central pyrazine nucleus, resulting in the identification of potent and selective compounds with improved drug-like properties. Notably, compound <b>1</b> was used to develop the first GluN2A NAM-based radioligand, and compound <b>11</b> showed improved pharmacokinetics and dose-dependent receptor occupancy in vivo. Thus, we provide an array of powerful new tools for the study of GluN2A receptors.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"68 4","pages":"4672–4693 4672–4693"},"PeriodicalIF":6.8000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Design, Synthesis, and Characterization of GluN2A Negative Allosteric Modulators Suitable for In Vivo Exploration\",\"authors\":\"François P. Bischoff*, Sven Van Brandt, Marcel Viellevoye, Michel De Cleyn, Michel Surkyn, Rodrigo J. Carbajo, Maria Dominguez Blanco, Berthold Wroblowski, Nathan K. Karpowich, Ruth A. Steele, Celine Schalk-Hihi, Robyn Miller, David Duda, Paul Shaffer, Scott Ballentine, Sirak Simavorian, Brian Lord, Robert A. Neff, Pascal Bonaventure and Harrie J. M. Gijsen*, \",\"doi\":\"10.1021/acs.jmedchem.4c0275110.1021/acs.jmedchem.4c02751\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p ><i>N</i>-Methyl-<span>d</span>-aspartate receptors are ionotropic glutamate receptors that mediate fast excitatory neurotransmission in the central nervous system. These receptors play essential roles in synaptic plasticity, learning, and memory and are implicated in various neuropathological and psychiatric disorders. Selective modulation of NMDAR subtypes, particularly GluN2A, has proven challenging. The <b>TCN-201</b> derivatives <b>MPX-004</b> and <b>MPX-007</b> are potent and selective for GluN2A receptors, yet their physical properties limit their in vivo utility. In this study, we optimized the <b>MPX-004</b>/<b>MPX-007</b> scaffold by modifying the linker region between the distal halogenated aromatic ring and the central pyrazine nucleus, resulting in the identification of potent and selective compounds with improved drug-like properties. Notably, compound <b>1</b> was used to develop the first GluN2A NAM-based radioligand, and compound <b>11</b> showed improved pharmacokinetics and dose-dependent receptor occupancy in vivo. Thus, we provide an array of powerful new tools for the study of GluN2A receptors.</p>\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"68 4\",\"pages\":\"4672–4693 4672–4693\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-02-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c02751\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c02751","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
摘要
n -甲基-d-天冬氨酸受体是在中枢神经系统中介导快速兴奋性神经传递的嗜离子性谷氨酸受体。这些受体在突触可塑性、学习和记忆中起着重要作用,并与各种神经病理和精神疾病有关。选择性调制NMDAR亚型,特别是GluN2A,已被证明具有挑战性。TCN-201衍生物MPX-004和MPX-007对GluN2A受体具有强效和选择性,但它们的物理性质限制了它们在体内的应用。在本研究中,我们通过修饰远端卤代芳香环与吡嗪中心核之间的连接区域,对MPX-004/MPX-007支架进行了优化,从而鉴定出具有改善药物样性质的强效和选择性化合物。值得注意的是,化合物1被用于开发第一个基于GluN2A nam的放射性配体,化合物11在体内表现出改善的药代动力学和剂量依赖性受体占用。因此,我们为GluN2A受体的研究提供了一系列强大的新工具。
Design, Synthesis, and Characterization of GluN2A Negative Allosteric Modulators Suitable for In Vivo Exploration
N-Methyl-d-aspartate receptors are ionotropic glutamate receptors that mediate fast excitatory neurotransmission in the central nervous system. These receptors play essential roles in synaptic plasticity, learning, and memory and are implicated in various neuropathological and psychiatric disorders. Selective modulation of NMDAR subtypes, particularly GluN2A, has proven challenging. The TCN-201 derivatives MPX-004 and MPX-007 are potent and selective for GluN2A receptors, yet their physical properties limit their in vivo utility. In this study, we optimized the MPX-004/MPX-007 scaffold by modifying the linker region between the distal halogenated aromatic ring and the central pyrazine nucleus, resulting in the identification of potent and selective compounds with improved drug-like properties. Notably, compound 1 was used to develop the first GluN2A NAM-based radioligand, and compound 11 showed improved pharmacokinetics and dose-dependent receptor occupancy in vivo. Thus, we provide an array of powerful new tools for the study of GluN2A receptors.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.